| |
|
|
MADISON, Wisconsin - July 31, 2000--SLIL Biomedical Corp. announced the addition of Jere E. Goyan, Ph.D., to its Board of Directors. Dr. Goyan served as Commissioner of the Food and Drug Administration from 1979 until 1981. He is currently President of Goyan and Hart Associates and Chairman of the Board of Directors of SciClone Pharmaceuticals. From 1967 through 1992, Dr. Goyan was Dean of the School of Pharmacy at the University of California, San Francisco. Dr. Goyan was President and Chief Operating Officer of Alteon, Inc. from 1993 though 1998. Dr. Goyan currently serves as on the Board of Directors of Boehringer Ingelheim Pharmaceuticals Corporation, Emisphere Technologies and PenWest Pharmaceuticals. "We are delighted to have Dr. Goyan join our board" said Peter Molloy, SLIL’s CEO and President. "With SLIL’s pipeline of potential drugs and imminent clinical trials, Dr. Goyan’s expertise and insights will be invaluable in helping to guide our efforts," he added. Dr. Goyan served as President of the American Association of Colleges of Pharmacy and of the American Associations of Pharmaceutical Scientists. He was the first pharmacist elected to the Institute of Medicine and has received numerous awards, including the Remington medal in 1992. Dr. Goyan holds a doctorate in Pharmaceutical Chemistry from the University of California, Berkeley and a bachelor of science degree from the School of Pharmacy, University of California, San Francisco. SLIL Biomedical Corp. is an early-stage drug discovery company focused on developing new treatments to fight cancer. SLIL is a leader in the development of novel polyamine analogs as anti-cancer agents and has proprietary Tumor Targeting and Delivery technologies (TTD™). The Company currently has a pipeline of 16 lead compounds from these technologies. SLIL also has an exclusive license to the Sequential Pathogenesis Model technology from the University of California-San Francisco that has far reaching potential diagnostic and prognostic applications for cancer and other diseases. SLIL has its headquarters and drug discovery activities in Madison, Wisconsin and additional research facilities, dedicated to the Sequential Pathogenesis Model technology, in Menlo Park, California. SOURCE: SLIL Biomedical Corp. Contact: Marla K. Johnson SLIL Biomedical Corp.
|